INO241115C15000
- 0.10
- 0.000.00%
Inovio Pharmaceuticals Newsroom
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Inovio Pharmaceuticals Analyst Ratings
RBC Capital Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Cuts Target Price to $6
RBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Inovio Pharmaceuticals Analyst Ratings
RBC Cuts Price Target on Inovio Pharmaceuticals to $7 From $8, Keeps Sector Perform, Speculative Risk
Inovio Pharma Price Target Cut to $33.00/Share From $40.00 by Oppenheimer
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS) and Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals (INO) Receives a Buy From Oppenheimer
Inovio Pharmaceuticals Analyst Ratings
RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $8
Inovio Pharmaceuticals: Hold Rating Amidst Financial Concerns and INO-3107 Development Delays
RBC Cuts Price Target on Inovio Pharmaceuticals to $8 From $11, Keeps Sector Perform, Speculative Risk
Inovio Pharmaceuticals: Maintaining Buy Rating Amid BLA Submission Delay
Analysts Conflicted on These Healthcare Names: Daiichi Sankyo Company (OtherDSKYF), Inovio Pharmaceuticals (INO) and Molina Healthcare (MOH)
Inovio Pharmaceuticals Analyst Ratings
Inovio Pharmaceuticals Receives 'Buy' Rating Amidst UK Regulatory Advancements and Promising RRP Treatment Outlook
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals: Hold Rating Amidst Clinical Progress and Financial Caution